Infographic: Navigating through the clinical trials of monoclonal antibodies targeting the CGRP pathway
The advent of new preventive medication is revolutionizing the migraine treatment landscape. As of March 2021, three monoclonal antibodies (mAbs) targeting the calcitonin gene-rel
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.
Log InNot registered yet? Register now